New Data Advance ATH434 as Neurodegeneration treatment
Filed with ASX · · 4 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Expanded ATH434 Phase 2 Clinical Development Program
- Form 20-F
- Appendix 4E & Annual Report 2021
- New US Patent Expands Neurodegeneration Treatment Portfolio
- New Publication Demonstrates ATH434 is Neuroprotective
Later from Alterity Therapeutics
- Chairmans Address 2021 Annual General Meeting
- ATH Annual General Meeting Presentation
- First Regulatory Authorization to Proceed with Phase 2 Trial
- New US Patent for Compounds to Treat Neurodegeneration
- Response to ASX Query
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics